Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia) (DC 7719) | VA Rating Tool

Diagnostic Code7719
CategoryThe Hemic and Lymphatic Systems
SubcategoryThe Hematologic and Lymphatic Systems
Also Known AsChronic myelogenous leukemia, Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia)
CFR Section4.117
Rating Criteria
Rating Criteria
100% Note (2): A 100 percent evaluation shall be assigned as of the date of hospital admission for peripheral blood or bone marrow stem cell transplant; or during the period of treatment with chemotherapy (including myelosuppressants). Six months following hospital discharge or, in the case of chemotherapy treatment, six months after completion of treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any reduction in evaluation based upon that or any subsequent examination shall be subject to the provisions of ยง 3.105 of this chapter
100% Requiring peripheral blood or bone marrow stem cell transplant, or continuous myelosuppressive or immunosuppressive therapy treatment
60% Requiring intermittent myelosuppressive therapy, or molecularly targeted therapy with tyrosine kinase inhibitors, or interferon treatment when not in apparent remission
30% In apparent remission on continuous molecularly targeted therapy with tyrosine kinase inhibitors